DPS-102: Phase II start

In December, Dermipsor will begin a double-blind, U.S. Phase II trial (2008-103) to compare topical DPS-102 vs. placebo, calcipotriol monotherapy, or nicotinamide monotherapy in 160 patients. The comp...